Prescribing information

 

Are you looking to optimise the well being of your patients with myelofibrosis? Listen to Professor Mary Frances McMullin and Clinical Nurse Specialist Caroline Kerr as they share their clinical experience of the impact of myelofibrosis and how they currently manage their patients’ treatment. 

“...managing the disease burden is crucial to minimise impact on daily life. Treatment should improve. The therapies should improve, both symptoms and quality of life.”

Professor Mary Frances McMullin

Professor Mary Frances McMullin

 

“On an emotional level, increasing numbers of patients need support and psychological advice; and in a way, this is where COVID has been good, because now everything’s done online; whereas before, we had to wait for long periods of time for counselling appointments.”

Nurse Specialist Caroline Kerr

Nurse Specialist Caroline Kerr

 

In this webinar, Clinical Nurse Specialist Caroline Kerr (Macmillan Leukaemia CNS in the regional haematology unit in Belfast) and Professor Mary Frances McMullin (Queen’s University, Belfast) discuss their first-hand experience of managing symptoms in patients with myelofibrosis, including the challenges of tracking personal, subjective symptoms and how clinicians may not always recognise their patients’ most troublesome symptom.

Professor Mary Frances McMullin introduces the topics to be covered in the webinar, before illustrating the burden faced by patients with myelofibrosis with a real patient case. Professor McMullin discusses how this patient first presented, and the evolution of her disease over 20+ years. She then delves into findings from the Landmark survey, the COMFORT studies and the MOSAICC study.

Watch Professor McMullin talk about her clinical experience of patients with myelofibrosis, as well as key insights from three important studies looking into patients’ quality of life.

 

Prescribing information and adverse event reporting

Caroline Kerr further discusses the realities of symptom burden in patients with myelofibrosis, and the value of MPN10 scoring in addressing symptom management clinically by capturing and tracking subjective experiences.

Hear Caroline share her experience of tracking symptom burden in patients with myelofibrosis using the MPN10 symptom tracker.

 

Prescribing information and adverse event reporting

Professor McMullin returns to her case study to reflect on treatment with ruxolitinib for the debilitating symptoms of myelofibrosis. The design and findings of key clinical trials for ruxolitinib – COMFORT-1 and COMFORT-2 – are discussed.

Listen to Professor McMullin as she explores the symptomatic and quality of life improvements that can be seen in patients treated with ruxolitinib.

 

Prescribing information and adverse event reporting

Rate this content: 
Average: 4 (1 vote)
UK | July 2022 | 138755-1
×

Ask Speakers

×

Medical Information Request

Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard. Adverse events should also be reported to Novartis via [email protected] or online through the pharmacovigilance intake (PVI) tool at www.report.novartis.com
If you have a question about the product, please contact Medical Information on 01276 698370 or by email at [email protected]